Product Details

Uniprot No.

Target Names

Alternative Names

Peptidyl-prolyl cis-trans isomerase A (PPIase A) (EC 5.2.1.8) (Cyclophilin A) (Cyclosporin A-binding protein) (Rotamase A) [Cleaved into: Peptidyl-prolyl cis-trans isomerase A, N-terminally processed], PPIA, CYPA

Species Reactivity

Human

Immunogen

Recombinant Human PPIA protein

Immunogen Species

Homo sapiens (Human)

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

hIgG1

Clone No.

11B12

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4

Form

Liquid

Tested Applications

ELISA, IF, FC

Recommended Dilution

Application	Recommended Dilution
IF	1:50-1:200
FC	1:50-1:200

Protocols

ELISA Protocol
Immunofluorescence (IF) Protocol
Flow Cytometry (FC) Protocol

Troubleshooting and FAQs

Antibody FAQs

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Description

Peptidyl-prolyl cis-trans isomerase A, commonly known as Cyclophilin A, serves as a critical molecular chaperone that catalyzes the cis-trans isomerization of proline residues in proteins, facilitating proper protein folding and cellular homeostasis. Beyond its enzymatic role, PPIA participates in diverse biological processes including immune regulation, viral replication, and inflammatory signaling, making it a target of significant interest in immunology, infectious disease research, and studies of cellular stress responses. Its well-characterized interaction with the immunosuppressant cyclosporin A has established PPIA as a key player in transplant biology and autoimmune disease research.

This recombinant monoclonal antibody, clone 11B12, offers researchers the reproducibility and consistency that recombinant technology provides. Because the antibody sequence is defined and produced in controlled expression systems, you can expect uniform performance across experiments and over time, eliminating the lot-to-lot variability that can complicate long-term studies or multi-site collaborations. The human IgG1 isotype format and affinity-chromatography purification ensure high specificity for human PPIA detection.

Validation studies demonstrate reliable performance in immunofluorescence applications, where the antibody successfully detected PPIA in both HeLa and A431 cell lines at dilutions of 1:30, revealing the expected cytoplasmic localization pattern. Flow cytometry analysis using Raji cells confirmed specific detection with clear separation from isotype control, supporting quantitative studies of PPIA expression at the single-cell level. These validated applications provide flexibility for researchers investigating PPIA in fixed and permeabilized cell preparations.

This antibody supports investigations into protein folding mechanisms, cyclosporin A-mediated immunosuppression, viral pathogenesis, and inflammatory disease pathways where PPIA dysregulation has been implicated.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Related Products

Target Background

Function

Catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides. Exerts a strong chemotactic effect on leukocytes partly through activation of one of its membrane receptors BSG/CD147, initiating a signaling cascade that culminates in MAPK/ERK activation. Activates endothelial cells (ECs) in a proinflammatory manner by stimulating activation of NF-kappa-B and ERK, JNK and p38 MAP-kinases and by inducing expression of adhesion molecules including SELE and VCAM1. Induces apoptosis in ECs by promoting the FOXO1-dependent expression of CCL2 and BCL2L11 which are involved in EC chemotaxis and apoptosis. In response to oxidative stress, initiates proapoptotic and antiapoptotic signaling in ECs via activation of NF-kappa-B and AKT1 and up-regulation of antiapoptotic protein BCL2. Negatively regulates MAP3K5/ASK1 kinase activity, autophosphorylation and oxidative stress-induced apoptosis mediated by MAP3K5/ASK1. Necessary for the assembly of TARDBP in heterogeneous nuclear ribonucleoprotein (hnRNP) complexes and regulates TARDBP binding to RNA UG repeats and TARDBP-dependent expression of HDAC6, ATG7 and VCP which are involved in clearance of protein aggregates. Plays an important role in platelet activation and aggregation. Regulates calcium mobilization and integrin ITGA2B:ITGB3 bidirectional signaling via increased ROS production as well as by facilitating the interaction between integrin and the cell cytoskeleton. Binds heparan sulfate glycosaminoglycans. Inhibits replication of influenza A virus (IAV). Inhibits ITCH/AIP4-mediated ubiquitination of matrix protein 1 (M1) of IAV by impairing the interaction of ITCH/AIP4 with M1, followed by the suppression of the nuclear export of M1, and finally reduction of the replication of IAV.; (Microbial infection) May act as a mediator between human SARS coronavirus nucleoprotein and BSG/CD147 in the process of invasion of host cells by the virus.; (Microbial infection) Stimulates RNA-binding ability of HCV NS5A in a peptidyl-prolyl cis-trans isomerase activity-dependent manner.

Gene References into Functions

Molecular structure of cyclophilin A in complex with alispovir has been presented. PMID: 30198892
Cyclophilin A is required for HIV-1 Tat palmitoylation . PMID: 29884859
These results suggested that the CyPA located on SV-HUC-1 cell membranes may be the potential receptor of Mycoplasma genitalium adhesion protein (MgPa), which could provide an experimental basis for elucidating the function of MgPa and the possible pathogenic mechanism of M. genitalium. PMID: 29551599
increased serum cyclophilin A concentrations could reflect trauma severity and unfavorable outcome after head trauma, substantializing cyclophilin A as a potential biomarker for prognostic prediction of TBI PMID: 29885319
Here, the binding site of AIF(Delta1-121) and AIF(370-394) on CypA has been mapped by NMR spectroscopy and biochemical studies, and a molecular model of the complex has been proposed. The authors show that AIF(370-394) interacts with CypA on the same surface recognized by AIF(Delta1-121) protein and that the region is very close to the CypA catalytic pocket. PMID: 28442737
CyPA was significantly increased in convalescent COPD patients and further elevated in COPD patients with acute exacerbation. PMID: 29403273
CypA expression was not an independent prognostic factor, but correlated with poor prognosis of lung adenocarcinoma PMID: 29027312
Extracellular cyclophilin A augments platelet-dependent thrombosis and thromboinflammation. PMID: 28981554
the increased expression of CyPA in ectopic endometrial tissue is associated with endometrioma recurrences and vascularity. PMID: 29081463
Taken together, these findings reveal an essential role of CypA in boosting RIG-I-mediated antiviral immune responses by controlling the ubiquitination of RIG-I and MAVS. PMID: 28594325
Data show that cyclophilin A (CypA) is up-regulated in oral squamous cell carcinoma (OSCC) arising from oral submucous fibrosis (OSF). PMID: 27533088
K308 of NS5A is indispensable for both RNA and NS5B binding, whereas W316 is essential for protein-protein interactions with CypA and NS5B. PMID: 27676132
PPIA is differentially expressed in lesional biopsy specimens from patients with atopic eczema relative to normal skin PMID: 28479159
inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) is an intracellular target of the PPIA-Sanglifehrin A binary complex. PMID: 28076787
these data suggest that CypA-NS4B interaction regulates Yellow fever virus (YFV )replication. Finally, we present the first evidence that YFV inhibition may depend on NS4B-CypA interaction. PMID: 28317380
This report reviews the literature related to the mechanism of CypA-dependent cytokine secretion and discusses this factor as a possible therapeutic target in inflammatory diseases. PMID: 28729360
Networks of dynamic allostery regulate cyclophilin A function. PMID: 28089447
Results show that CypA is overexpressed in human hepatocellular carcinoma (HCC) and is associated with TNM stage and suggest that CypA may be involved in the development and progression of HCC. PMID: 28739738
Plasma CyPA levels can be used to predict all-cause death, rehospitalization, and coronary revascularization in patients with coronary artery disease. PMID: 28153875
data suggest that rs6850 G SNP enhances HIV-1 replication through upregulation of CypA expression following HIV-1 infection PMID: 27088296
These results demonstrate that SUN2 is required for the optimal activation and proliferation of primary CD4 T cells and suggest that the disruption of these processes explains the contribution of endogenous SUN2 to HIV infection in primary lymphocytes and show that CypA is not required for the decreased infection observed in SUN2-silenced cells. PMID: 28077629
The critical roles of Cyclophilin A in mediating or inhibiting viral infections. [review] PMID: 27033630
Overexpression of CYPA is associated with colorectal cancer. PMID: 27468721
PPIA may play a pivotal role in hepatocellular carcinoma (HCC) by regulating cell growth and could serve as a novel marker and therapeutic molecular target for HCC patients. PMID: 27397650
found to be coupled and temporally dispersed, ranging over 4 to 5 orders of magnitude. Finally, using network centrality measures we demonstrate the changes in the communication network, connectivity, and influence of CypA residues upon substrate binding, mutation, and during catalysis. PMID: 27071107
Enhanced platelet-bound CyPA is associated with hypertension and hypercholesterolemia in stable coronary artery disease patients. In patients with acute myocardial infarction platelet-bound CyPA is significantly decreased. PMID: 26084004
results indicate that the PPIA SNP rs6850: A > G is associated with increased risk for elevated plasma levels of cyclophilin A and coronary artery disease in patients with and without type 2 diabetes PMID: 26702934
the states of phosphorylation of Cyp A by Akt can influence the progress of the cell cycle in multiple myeloma. PMID: 26833980
review of PPIA polymorphisms and what is known about their impact on the replication cycle and course of disease for different viral infections PMID: 26281011
The present knowledge on the role of cyclophilin A during coronavirus replication is summarized (Review) PMID: 26318518
CsA and FK506 might interfere with selected effector T cell functions via a CrkII-, but not CrkI-dependent mechanisms. PMID: 26792730
Extracellular CyPA activates platelets via cluster of differentiation 147-mediated phosphoinositid-3-kinase/Akt-signaling, leading to enhanced adhesion and thrombus formation independently of intracellular CyPA. PMID: 25550208
Overexpression of CypA/WT protected the cells against cisplatin or H2O2-induced oxidative damage, however, the CypA/P16S mutant had no effect. These findings suggested that CypA exhibits a protective antioxidant effect PMID: 25738284
The poor prognosis of esophageal cancer patients was associated with high expression of CypA. PMID: 25420107
These results indicate a special function mode for CypA of playing more important roles in the early stage of gastric tumorigenesis. PMID: 26008617
Cyclophilin A regulates HIV-1 replication kinetics and infectivity, modulates sensitivity to host restriction factors, and cooperates in the transit of the pre-integration complex into the nucleus of infected cells. PMID: 25445708
The frequency of immunihistochemistry detected cyclophilin A protein expression was found to be equal in tumor of both histotypes. PMID: 24272759
Cyclophilin A regulates JNK/p38-MAPK signaling through its physical interaction with ASK1. PMID: 26095851
Decrease in plasma cyclophilin A concentration at 1 month after myocardial infarction predicts better left ventricular performance and synchronicity at 6 months. PMID: 25552928
review of the role of cyclophilin A and CD147 in kidney diseases and potential implications for treatment of kidney diseases PMID: 25580061
These findings suggest that eCyPA-CD147 signaling promotes the bone marrow homing of B cell malignancies and offer a compelling rationale for exploring this axis as a therapeutic target for these malignancies. PMID: 26005854
the results indicated that the combination of ENO1 and CYPA can serve as a potential molecular marker for the early detection of NPC. PMID: 24998431
CypA is secreted from CCA cells and enhances cell proliferation in an autocrine/paracrine manner, at least via direct binding with CD147, which may activate the ERK1/2 and p38 MAPK signaling pathways. PMID: 25296734
The extracellular portion of cyclophilin A probably plays an important role in human diseases associated with acute or chronic inflammation. PMID: 24713575
The present data demonstrate that immunophilins regulate CrkII, but not CrkI activity in T cells and suggest that CsA and FK506 inhibit selected effector T cell functions via a CrkII-dependent mechanism. PMID: 25225668
These results suggested that,CypA, a gene downstream of HIF-1alpha, could promote the development of PDAC. PMID: 24662981
Cyclophilin A catalyzes proline isomerization by an electrostatic handle mechanism. PMID: 24982184
These data demonstrate that, while CypA promotes reverse transcription under all conditions tested here, its effect on HIV-1 infectivity correlates more closely with effects on nuclear entry of the viral cDNA. PMID: 24479545
Inhibition of the AIF/CypA complex protects against intrinsic death pathways induced by oxidative stress. PMID: 24434516
Patients with type 2 diabetes have higher circulating levels of cyclophilin A than the normal population. PMID: 24502618

Hide All

Subcellular Location

Cytoplasm. Secreted. Nucleus.

Protein Families

Cyclophilin-type PPIase family, PPIase A subfamily

Database Links

HGNC: 9253

OMIM: 123840

KEGG: hsa:5478

STRING: 9606.ENSP00000419425

UniGene: Hs.356331

Message

Product >> Product Name：
Product >> Code：
Name： *
Email： *
Company/Organization：
Phone：
Since emails may get flagged by spam filters occasionally, we recommend leaving your phone number as a precaution. Your information is safe with us.
Question/Comment： *
Your Region： *
I'd like to receive email newsletters from Cusabio

Yes

No
How do you know CUSABIO?

Email

Distributor

Search engine

Advertisement

Others
CAPTCHA verification：
Please enter the characters shown. Click the image to refresh if unclear.

Code	CSB-RA351810MA1HU
Size	US$210
	Order now
Image	Immunofluorescence staining of Hela cell with CSB-RA351810MA1HU at 1:30 ,counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Human IgG(H+L). Immunofluorescence staining of A431 cell with CSB-RA351810MA1HU at 1:30 ,counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Human IgG(H+L). Overlay Peak curve showing Raji cells stained with CSB-RA351810MA1HU (red line) at 1:100. The cells were fixed in 4% formaldehyde and permeated by 0.2% TritonX-100 for 10min. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1ug/110⁶cells) for 45min at 4℃. The secondary antibody used was Fluorescein (FITC) AffiniPure Goat Anti-Human IgG, Fcγ fragment specific at 1:200 dilution for 35 min at 4℃.Control antibody (green line) was human IgG1 (1ug/110⁶cells) used under the same conditions. Acquisition of >10,000 events was performed.
Have Questions?	Leave a Message or Start an on-line Chat

PPIA Recombinant Monoclonal Antibody

Product Details

Related Products

Customer Reviews and Q&A

Target Background